Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AR 101

Drug Profile

AR 101

Alternative Names: AR-101-Aimmune-Therapeutics; AR101; Arachis hypogaea Allergen Powder-dnfp; Characterised-peanut-allergen-oral-immunotherapy-ARC; CPNA-Aimmune-Therapeutics; defatted powder of Arachis hypogaea L; PALFORZIA; Peanut (Arachis hypogaea) allergaen powder-dnfp; Peanut Allergen Powder-dnfp; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics; semen; semen (peanuts)

Latest Information Update: 23 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergen Research Corporation
  • Developer Aimmune Therapeutics; Regeneron Pharmaceuticals; Sanofi
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peanut hypersensitivity

Most Recent Events

  • 20 Nov 2023 Positive adverse events data from a phase III POSEIDON trial in Peanut hypersensitivity (In adolescents, In children) released by Stallergenes Greer
  • 04 Sep 2023 Stallergen acquires AR 101 from Nestle helath Sciences
  • 27 Apr 2023 Aimmune Therapeutics completes a phase III ARC008 trial for Peanut hypersensitivity (In children, In adolescents, In adults) in USA, France, Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden and United Kingdom (PO) (NCT03292484) (EudraCT2017-001334-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top